{"groups":[{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 8 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG000","title":"Dose Escalation Cohort 1 (10 mL SQL70 and 8 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 16 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG001","title":"Dose Escalation Cohort 2 (10 mL SQL70 and 16 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 32 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG002","title":"Dose Escalation Cohort 3 (10 mL SQL70 and 32 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 58 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG003","title":"Dose Escalation Cohort 4 (10 mL SQL70 and 58 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 85 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG004","title":"Dose Escalation Cohort 5 (10 mL SQL70 and 85 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 125 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG005","title":"Dose Escalation Cohort 6 (10 mL SQL70 and 125 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 185 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG006","title":"Dose Escalation Cohort 7 (10 mL SQL70 and 185 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 250 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG007","title":"Dose Escalation Cohort 8 (10 mL SQL70 and 250 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 315 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG008","title":"Dose Escalation Cohort 9 (10 mL SQL70 and 315 mg/m^2 of SQP33)"},{"description":"20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 85 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG009","title":"Dose Escalation Cohort (20 mL SQL70 and 85 mg/m^2 of SQP33)"},{"description":"20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 125 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG010","title":"Dose Escalation Cohort (20 mL SQL70 and 125 mg/m^2 of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 185 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced or metastatic solid tumors","id":"FG011","title":"Cohort A (10 mL SQL70 and 185 mg/m^2 of SQP33)"},{"description":"20 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 250 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with soft tissue sarcomas of the extremity","id":"FG012","title":"Phase 2a Expansion Group 1 (Extremity STS) (20 mL SQL70 and 250 mg/m^2/Day of SQP33)"},{"description":"10 mL of SQL70 injected intratumorally on Day 1 of each 21-day cycle into a single lesion with 500 mg/m\\^2 of SQP33 infused on Day 1 and 2 with 250 mg/m\\^2 of SQP33 infused on each Day 3 in subjects with locally advanced, unresectable or metastatic soft tissue sarcomas who are anthracycline naïve","id":"FG013","title":"P2a Grp 2 (10 mL SQL70 and 500 mg/m^2/ of SQP33 for 2 Days and and 250 mg/m^2/ of SQP33 for 1 Day)"},{"description":"10 mL of SQL70 injected intratumorally on Day with 250 mg/m\\^2 of SQP33 infused each day on Day 1 through Day 5 in subjects with locally advanced, unresectable or metastatic soft tissue sarcomas who are anthracycline naïve","id":"FG014","title":"P2a Grp 2 (10 mL SQL70 and 250 mg/m^2/Day of SQP33 for Five Days)"}],"periods":[{"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"6"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"1"},{"groupId":"FG003","numSubjects":"3"},{"groupId":"FG004","numSubjects":"3"},{"groupId":"FG005","numSubjects":"4"},{"groupId":"FG006","numSubjects":"4"},{"groupId":"FG007","numSubjects":"7"},{"groupId":"FG008","numSubjects":"6"},{"groupId":"FG009","numSubjects":"5"},{"groupId":"FG010","numSubjects":"3"},{"groupId":"FG011","numSubjects":"1"},{"groupId":"FG012","numSubjects":"2"},{"groupId":"FG013","numSubjects":"6"},{"groupId":"FG014","numSubjects":"6"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"0"},{"groupId":"FG005","numSubjects":"0"},{"groupId":"FG006","numSubjects":"0"},{"groupId":"FG007","numSubjects":"0"},{"groupId":"FG008","numSubjects":"0"},{"groupId":"FG009","numSubjects":"0"},{"groupId":"FG010","numSubjects":"0"},{"groupId":"FG011","numSubjects":"0"},{"groupId":"FG012","numSubjects":"0"},{"groupId":"FG013","numSubjects":"0"},{"groupId":"FG014","numSubjects":"0"}],"type":"NOT COMPLETED"}],"title":"Overall Study"}]}